As the pharmaceutical landscape evolves, small-molecule CDMOs will be essential in balancing supply and demand, driving innovation, and improving patient outcomes. They must continue embracing innovation and strategic agility to survive and thrive in this complex environment.
The post Building Resilience: CDMO Strategies for Drug Supply Chain Stability appeared first on MedCity News.